Regenxbio
RGNX
165 hedge funds and large institutions have $504M invested in Regenxbio in 2026 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 62 increasing their positions, 52 reducing their positions, and 35 closing their positions.
242% more call options, than puts
Call options by funds: $7.13M | Put options by funds: $2.08M
42% more capital invested
Capital invested by funds: $355M → $504M (+$149M)
19% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 52
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.93% less ownership
Funds ownership: 82.52% → 81.59% (-0.93%)
7% less funds holding
Funds holding: 178 → 165 (-13)
29% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 35
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$10.7M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$5.55M |
| 3 |
BlackRock
New York
|
+$5.1M |
| 4 |
D.E. Shaw & Co
New York
|
+$3.54M |
| 5 |
Lazard Asset Management
New York
|
+$3.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$11M |
| 2 |
JP Morgan Chase
New York
|
-$10.5M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$6.73M |
| 4 |
IHAM
Integral Health Asset Management
New York
|
-$5.81M |
| 5 |
Goldman Sachs
New York
|
-$3.47M |
RGNX Hedge Fund Activity: Q2 2026 in Review
165 institutional investors reported a position in Regenxbio (RGNX) for Q2 2026, worth a combined $504M — up 42% from $355M a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of RGNX and 25 opened new positions — a net loss of 10 holders — while 52 trimmed existing stakes and 62 added.
The largest buyer was Marshall Wace, opening a new position worth an estimated $10.7M. The largest seller was Qube Research & Technologies (QRT), exiting entirely with an estimated $11M sold.
- 165 institutional investors held Regenxbio (RGNX) as of Q2 2026, down from 178 in Q1 2026.
- Funds reported $504M of Regenxbio stock for Q2 2026, up 42% quarter-over-quarter.
- 25 funds opened new Regenxbio positions in Q2 2026 and 35 closed out, a net change of -10 holders.
- The largest Regenxbio buyer in Q2 2026 was Marshall Wace, an estimated $10.7M added.
- The largest Regenxbio seller in Q2 2026 was Qube Research & Technologies (QRT), an estimated $11M sold.
Based on aggregated 13F filings for Q2 2026.